Lantheus Holdings, Inc. Cost, Depreciation, Amortization and Depletion
Lantheus Holdings, Inc. (LNTH) reported Cost, Depreciation, Amortization and Depletion of $5.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostDepreciationAmortizationAndDepletion · last filed 2026-08-06
- Lantheus Holdings, Inc. cost, depreciation, amortization and depletion for the quarter ending 2026-06-30 was $5.90M, a 15.69% increase year-over-year.
- Lantheus Holdings, Inc. cost, depreciation, amortization and depletion for the quarter ending 2026-03-31 was $6.00M, a 9.09% increase year-over-year.
- Lantheus Holdings, Inc. cost, depreciation, amortization and depletion for the quarter ending 2025-12-31 was $6.20M, a 16.98% increase year-over-year.
- Lantheus Holdings, Inc. cost, depreciation, amortization and depletion for the quarter ending 2025-09-30 was $5.60M, a 9.80% increase year-over-year.
- Lantheus Holdings, Inc. cost, depreciation, amortization and depletion for fiscal 2025 was $22.50M, a 10.29% increase from fiscal 2024.
- Lantheus Holdings, Inc. cost, depreciation, amortization and depletion for fiscal 2024 was $20.40M, a 54.55% increase from fiscal 2023.
- Lantheus Holdings, Inc. cost, depreciation, amortization and depletion for fiscal 2023 was $13.20M, a 3.65% decline from fiscal 2022.
- Lantheus Holdings, Inc. cost, depreciation, amortization and depletion for fiscal 2022 was $13.70M, a 3.79% increase from fiscal 2021.
| Period end | Cost, Depreciation, Amortization and Depletion 3 month | Cost, Depreciation, Amortization and Depletion 6 month | Cost, Depreciation, Amortization and Depletion 9 month | Cost, Depreciation, Amortization and Depletion 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.90M 10-Q · filed 2026-08-06 | $11.80M 10-Q · filed 2026-08-06 | $18.10M derived: sum of 3 quarters · filed 2026-08-06 | $23.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.00M 10-Q · filed 2026-05-07 | $12.20M derived: sum of 2 quarters · filed 2026-05-07 | $17.80M derived: sum of 3 quarters · filed 2026-05-07 | $22.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.80M derived: sum of 2 quarters · filed 2026-02-26 | $16.90M derived: sum of 3 quarters · filed 2026-08-06 | $22.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.60M 10-Q · filed 2025-11-06 | $10.70M derived: sum of 2 quarters · filed 2026-08-06 | $16.30M 10-Q · filed 2025-11-06 | $21.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.10M 10-Q · filed 2026-08-06 | $10.60M 10-Q · filed 2026-08-06 | $15.90M derived: sum of 3 quarters · filed 2026-08-06 | $21.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.50M 10-Q · filed 2026-05-07 | $10.80M derived: sum of 2 quarters · filed 2026-05-07 | $15.90M derived: sum of 3 quarters · filed 2026-05-07 | $20.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.40M derived: sum of 2 quarters · filed 2026-02-26 | $15.00M derived: sum of 3 quarters · filed 2026-02-26 | $20.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.10M 10-Q · filed 2025-11-06 | $9.70M derived: sum of 2 quarters · filed 2025-11-06 | $15.10M 10-Q · filed 2025-11-06 | $18.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.60M 10-Q · filed 2025-08-06 | $10.00M 10-Q · filed 2025-08-06 | $13.60M derived: sum of 3 quarters · filed 2026-02-26 | $16.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.40M 10-Q · filed 2025-05-07 | $9.00M derived: sum of 2 quarters · filed 2026-02-26 | $11.90M derived: sum of 3 quarters · filed 2026-02-26 | $15.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.50M derived: sum of 2 quarters · filed 2026-02-26 | $9.80M derived: sum of 3 quarters · filed 2026-02-26 | $13.20M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.90M 10-Q · filed 2024-11-06 | $6.20M derived: sum of 2 quarters · filed 2024-11-06 | $9.60M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $3.30M 10-Q · filed 2024-07-31 | $6.70M 10-Q · filed 2024-07-31 | ||
| 2023-03-31 | $3.40M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $13.70M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $13.20M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $12.50M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $10.30M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $10.10M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $14.80M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |